Omkar Speciality Chemicals FY26 loss, delayed filings

What the latest exchange updates show

Omkar Speciality Chemicals Limited has made multiple disclosures to stock exchanges around board actions, financial reporting, and operational matters. The updates include approval of FY26 audited financial statements, prior intimation of a board meeting to approve delayed financial statements for FY22 to FY25, and a separate update on sale approvals for two industrial plots. The company has also stated that trading in its equity shares remains suspended on BSE Limited and the National Stock Exchange of India Limited.

These filings matter because they map the company’s effort to regularise reporting after delays linked to the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. They also give investors a fresh view of the latest available operating performance and losses. The disclosures name the officer signing the communication and provide company contact details, which is typical in such regulatory filings.

Outcome of board meeting: FY26 financials approved

The company informed the Exchange regarding the outcome of a board meeting held on August 07, 2026. Separately, it also states that the Board of Directors met on June 12, 2026 and approved the standalone audited financial statements for the quarter and financial year ended March 31, 2026.

For Q4 FY26, revenue from operations was reported at ₹0.0082 crore, described as flat compared with the preceding quarter (Q3 FY26) and the corresponding quarter of the previous year. The net loss for Q4 FY26 stood at ₹0.3326 crore, compared with a net loss of ₹0.3284 crore in Q3 FY26. The company also reported that this represented a 1.28% quarter-on-quarter increase in loss.

For the full financial year ended March 31, 2026, total income was recorded at ₹0.1675 crore and net loss at ₹1.5888 crore. These numbers show continued losses alongside very low income for the year.

Key numbers snapshot (converted to ₹ crore)

Board meeting intimation: clearing delayed FY22 to FY25 statements

Omkar Speciality Chemicals also provided prior intimation to BSE and NSE under Regulation 29 of SEBI (LODR) Regulations, 2015 for an upcoming Board of Directors meeting scheduled for Friday, August 7, 2026. The agenda included consideration and approval of multiple pending financial statements across years.

The items listed included unaudited financial statements for the quarters September 2022 and December 2022, along with audited financial statements for the year ended March 31, 2023. In addition, the company planned to take up unaudited financial statements for all quarters and audited financial statements for the year ended March 31, 2024. The same coverage was indicated for the year ended March 31, 2025.

The company explained that it was unable to submit quarterly, half-yearly, and yearly financial results from financial year 2022 to 2025 because it was under CIRP and faced other operational constraints. This statement directly connects the reporting delays with the insolvency process.

Trading suspension and trading window note

The disclosure confirms that trading in the company’s equity shares remains suspended on both BSE Limited and the National Stock Exchange of India Limited. Because of the continuing suspension, the company said it has not issued a separate intimation regarding closure of the trading window for the board meeting. The stated reason is that the securities are not available for trading.

The letter was signed by Mahendra Kumar Jain, Additional Director (DIN: 09765526), on behalf of Omkar Speciality Chemicals Limited. This establishes responsibility for the communication, and aligns with standard exchange disclosure practice.

Property sale update: two MIDC plots approved for sale

In a separate general update, the company informed exchanges about the outcome of a board meeting held on June 25, 2026 under Regulation 30 of SEBI (LODR) Regulations, 2015. The board considered and approved the sale of two properties or units in the MIDC Industrial Area at Badlapur, District Thane.

The properties disclosed were Plot No. W 83 admeasuring 880 square metres and Plot No. W 93 admeasuring 720 square metres. The company stated it would keep the Stock Exchange informed of further developments regarding the sale transactions and would make necessary disclosures as required under applicable regulations. The filing did not provide transaction value or buyer details in the text provided.

Management and board composition disclosed

The material also lists an executive committee and board composition for Omkar Speciality Chemicals Limited. In the executive committee, Dipak Kumar Shaw is listed as Chief Executive Officer since 2026-05-26. Mahendra Kumar Jain is listed as Director of Finance/CFO, aged 69, since 2026-04-14, and Kuldeep Menaria is listed as Compliance Officer since 2026-04-14.

In the board composition table, Pravin Shivdas Herlekar is listed as Chairman, aged 76, since 2011-02-13. Other listed directors include Archana Prakash Dakhale (since 2020-09-27), Subhash Murlidhar Ambatkar (since 2019-02-13), and Ruhini Kumar Chakraborty (since 2026-05-26), along with names including Bhupeshkumar Jain and Muskan Pherwani with dates not specified in the provided table.

Market reference points available in the text

A market price reference is included: OMKARCHEM stock price is stated as ₹3.6 as of 8 Aug, 2026. The content also reiterates corporate actions context by listing a board meeting agenda entry dated 2026-08-07 with “Quarterly Results.”

Separately, the text includes a broader, unsorted exchange table of board meeting intimations for other listed companies, including Marine Electricals (India) Limited (meeting date 14-Aug-2026), HP Adhesives Limited (13-Aug-2026), Xelpmoc Design And Tech Limited (14-Aug-2026), Chavda Infra Limited (14-Aug-2026), and All E Technologies Limited (14-Aug-2026), along with their broadcast timestamps. These entries indicate a busy mid-August board-meeting calendar on the exchange system.

Analysis: why these disclosures matter

The most consequential element in the disclosures is the company’s stated intent to approve and publish delayed financial statements for FY22 to FY25 after CIRP-linked disruption. For investors, delayed filings reduce visibility, and exchange updates that lay out a timetable and scope of pending statements are a key compliance signal.

The FY26 numbers in the disclosure show extremely low income and continued losses. With revenue from operations at ₹0.0082 crore in Q4 FY26 and a quarterly net loss of ₹0.3326 crore, the gap between operating activity and costs remains significant in the reported period. The full-year loss of ₹1.5888 crore on total income of ₹0.1675 crore underlines that the company’s current scale of income, as disclosed, does not cover its cost structure.

The property sale approvals add an operational and balance-sheet development to track, although the filing does not specify consideration or timelines. Separately, the company’s note that trading is suspended on both BSE and NSE is a material constraint for shareholders, and it also explains why the company did not issue a trading window closure notice.

Conclusion

Omkar Speciality Chemicals’ latest filings combine FY26 audited results, a compliance roadmap to clear delayed FY22 to FY25 statements, and an approval to sell two MIDC industrial plots in Badlapur. The company has also confirmed that trading in its equity shares remains suspended on both major Indian exchanges. The next set of updates to watch, based on the disclosures, are further announcements tied to the board’s consideration of the pending financial statements and any subsequent disclosures on the property sale process.